Show notes
The Derms stay in Vienna for round two of EADV, where zombie-cell cream meets new pathways in HS and AD—plus a JAK surprise in PPP and reassuring pregnancy data.
The Derms stay in Vienna for round two of EADV, where zombie-cell cream meets new pathways in HS and AD—plus a JAK surprise in PPP and reassuring pregnancy data.